Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma (Q45399228)

14 December 2017

Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma (English)

1 reference

14 December 2017

16

1 reference

14 December 2017

Simone Ferrero

1

1 reference

14 December 2017

Luigia Monitillo

2

1 reference

14 December 2017

Barbara Mantoan

3

1 reference

14 December 2017

Daniela Barbero

4

1 reference

14 December 2017

Elisa Genuardi

5

1 reference

14 December 2017

Sara Barbiero

6

1 reference

14 December 2017

Elisa Bernocco

7

1 reference

14 December 2017

Daniele Caracciolo

8

1 reference

14 December 2017

Marco Ruella

9

1 reference

14 December 2017

Daniela Drandi

10

1 reference

14 December 2017

Manuela Zanni

11

1 reference

14 December 2017

Federica Renna

12

1 reference

14 December 2017

Chiara Lobetti Bodoni

13

1 reference

14 December 2017

Angela Gueli

14

1 reference

14 December 2017

Roberto Passera

15

1 reference

14 December 2017

Mario Boccadoro

17

1 reference

14 December 2017

Corrado Tarella

18

1 reference

14 December 2017

Marco Ladetto

19

1 reference

14 December 2017

5 June 2013

1 reference

14 December 2017

1 reference

14 December 2017

92

1 reference

14 December 2017

11

1 reference

14 December 2017

1503-1511

1 reference

Improved survival of follicular lymphoma patients in the United States.

14 December 2017

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1797-Y

Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1797-Y

Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1797-Y

Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1797-Y

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1797-Y

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1797-Y

Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1797-Y

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1797-Y

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1797-Y

Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1797-Y

Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1797-Y

Revised response criteria for malignant lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1797-Y

Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1797-Y

Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1797-Y

A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1797-Y

Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1797-Y

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1797-Y

10.1007/S00277-013-1797-Y

21 January 2018

Identifiers

DOI

1 reference

14 December 2017

1 reference